Soligenix Future Growth

Future criteria checks 0/6

Soligenix's earnings are forecast to decline at 17.3% per annum while its annual revenue is expected to grow at 3.3% per year. EPS is expected to grow by 0.8% per annum.

Key information

-17.3%

Earnings growth rate

0.8%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate3.3%
Future return on equityn/a
Analyst coverage

Low

Last updated20 Mar 2024

Recent future growth updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%

Dec 22

Soligenix announces $20M strategic convertible debt financing agreement

Dec 16

Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Nov 20
Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Earnings and Revenue Growth Forecasts

NasdaqCM:SNGX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261-11N/AN/A2
12/31/20251-10N/AN/A2
12/31/20241-9N/AN/A2
12/31/20231-6-9-9N/A
9/30/20231-8-10-10N/A
6/30/20231-10-11-11N/A
3/31/20231-10-12-12N/A
12/31/20221-14-13-13N/A
9/30/20221-15-12-12N/A
6/30/20221-15-12-12N/A
3/31/20221-15-11-11N/A
12/31/20211-13-12-12N/A
9/30/20211-13-13-13N/A
6/30/20211-12-13-13N/A
3/31/20212-12-13-13N/A
12/31/20202-18-11-11N/A
9/30/20203-15-10-10N/A
6/30/20203-16-9-9N/A
3/31/20204-15-8-8N/A
12/31/20195-9-8-8N/A
9/30/20195-10-8-8N/A
6/30/20195-9-6-6N/A
3/31/20195-8-8-8N/A
12/31/20185-9-7-7N/A
9/30/20186-8-7-7N/A
6/30/20186-7-7-7N/A
3/31/20185-8-6-6N/A
12/31/20175-7-7-7N/A
9/30/20176-5N/A-6N/A
6/30/20177-6N/A-6N/A
3/31/20179-4N/A-6N/A
12/31/201610-3N/A-5N/A
9/30/201612-5N/A-5N/A
6/30/201613-1N/A-4N/A
3/31/201611-4N/A-5N/A
12/31/20159-8N/A-5N/A
9/30/20158-4N/A-4N/A
6/30/20157-11N/A-5N/A
3/31/20157-8N/A-4N/A
12/31/20147-7N/A-2N/A
9/30/20146-8N/A-3N/A
6/30/20144-10N/A-4N/A
3/31/20143-12N/A-4N/A
12/31/20133-10N/A-4N/A
9/30/20133-12N/A-4N/A
6/30/20133-6N/A-3N/A
3/31/20133-4N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNGX's revenue (3.3% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: SNGX's revenue (3.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SNGX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.